News
PR: At this stage, the direct revenue from the company's DiOrion platform drug development services accounts for a small proportion of the company's overall operating income, which does not have a significant impact on the company's overall operating situation
Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments